We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04777760
Recruitment Status : Recruiting
First Posted : March 2, 2021
Last Update Posted : October 14, 2022
Sponsor:
Collaborator:
Children's Hospital of Chongqing Medical University
Information provided by (Responsible Party):
Chen Long,MD, Children's Hospital of Chongqing Medical University

Brief Summary:

In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS.

In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.


Condition or disease Intervention/treatment
Respiratory Distress Syndrome Preterm Birth Acute Respiratory Distress Syndrome Surfactant Dysfunction Drug: one dose of surfactant replacement Drug: two and more doses of surfactant replacement

Detailed Description:

To date, PS is not recommended to adult and pediatric ARDS. Meantime, systematic review indicates that PS does not demonstrate statistically significant beneficial effects on reducing the mortality and the rate of BPD in term and late preterm infants with meconium aspiration syndrome(MAS). Therefore, a reasonable speculation is that preterm infants with NARDS do not benefit from one dose of PS. And the speculation can explain why not all preterm infants with respiratory distress can be beneficial from PS. In the era of pre-NARDS, the preterm infants fulfilling the definition of NARDS may have been considered as NRDS in the first three days after birth.

According to the diagnostic criteria of NARDS, a key procedure for diagnosis of NARDS is to exclude the newborn infants with NRDS. But no detailed procedures are available to differentiate NRDS from NARDS.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)
Actual Study Start Date : January 1, 2021
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2024


Group/Cohort Intervention/treatment
one dose of surfactant
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
Drug: one dose of surfactant replacement
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant

two and more doses of surfactant
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
Drug: two and more doses of surfactant replacement
the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant




Primary Outcome Measures :
  1. bronchopulmonary dysplasia(BPD) [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with BPD

  2. death [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants die

  3. BPD and/or death [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with BPD and/or death

  4. the predictive powers of one dose of surfactant to diagnose NRDS [ Time Frame: seven days after birth ]
    the sensitivity and accuracy of one dose of surfactant to diagnose NRDS

  5. the predictive powers of two and more doses of surfactant to diagnose NARDS [ Time Frame: seven days after birth ]
    the sensitivity and accuracy of two and more doses of surfactant to diagnose NARDS


Secondary Outcome Measures :
  1. intraventricular hemorrhage(IVH) [ Time Frame: before discharge or 36 weeks' gestational age ]
    the preterm infants will be diagnosed with IVH

  2. air leak [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with air leak

  3. periventricular leukomalacia(PVL) [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with PVL

  4. necrotizing enterocolitis(NEC) [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with NEC

  5. patent ductus arteriosis(PDA) [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with PDA

  6. late-onset sepsis(LOS) [ Time Frame: at 36 weeks' gestational age or before discharge from hospital ]
    the preterm infants will be diagnosed with LOS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Minute to 24 Hours   (Child)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Preterm infants diagnosed with NRDS or NARDS were eligible. The diagnosis of NARDS was according to the criteria established by Montreux conference in 2017.The diagnosis of NRDS was according to the criteria established by European Consensus Guideline for the management of NRDS in 2019
Criteria

Inclusion Criteria:

Eligibility requirements for neonates were as follows:

  • The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth
  • The neonates will be diagnosed with NRDS or NARDS
  • The neonates will be at least administrated one dose of surfactant

Exclusion Criteria:

one of the following criteria will be needed

  • major congenital anomalies
  • chromosomal abnormalities
  • upper respiratory tract abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04777760


Contacts
Layout table for location contacts
Contact: Chen Long, MD, PhD +8613883559467 neuroclong@126.com

Locations
Layout table for location information
China, Chongqing
Chen Recruiting
Chongqing, Chongqing, China, 400042
Contact: Chen Long, MD,PhD    +8613883559467    neuroclong@126.com   
Sponsors and Collaborators
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Children's Hospital of Chongqing Medical University
Layout table for additonal information
Responsible Party: Chen Long,MD, director, Children's Hospital of Chongqing Medical University
ClinicalTrials.gov Identifier: NCT04777760    
Other Study ID Numbers: surfactant for NRDS and ARDS
First Posted: March 2, 2021    Key Record Dates
Last Update Posted: October 14, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: the data will be accessed after two years of study accomplishment
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: preliminary estimate in 2025

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Hyaline Membrane Disease
Premature Birth
Syndrome
Disease
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Pulmonary Surfactants
Respiratory System Agents